OncoMatch/Clinical Trials/NCT05544240
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Is NCT05544240 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SV-101 for metastatic cancer.
Treatment: SV-101 — SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/L; Lymphocyte count ≥ 1.0 x 10^9/L; Platelet count ≥ 100 x 10^9/L; Hemoglobin ≥ 9.0 g/dL; Bone marrow function without transfusion 30 days before first dosing
Kidney function
Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 or creatinine clearance calculated by Cockcroft-Gault equation ≥30 mL/
Liver function
Alanine aminotransferase ≤ 3x ULN; Aspartate aminotransferase ≤ 3x ULN; Total bilirubin ≤ ULN or ≤ 1.5x ULN with direct bilirubin ≤ ULN in subjects with documented Gilbert's Syndrome; Patients with liver metastases ≤5x ULN
Cardiac function
Has undergone a cardiac work-up and received cardiac clearance two months before first treatment
Adequate bone marrow, renal, and hepatic function, defined as follows: ... Has undergone a cardiac work-up and received cardiac clearance two months before first treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05544240 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify